NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
04/25/2023
Back to search
Official data from USPTO
GORYO CHEMICAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
GORYO CHEMICAL
ST13
US500000079309723Class
1, 5, 44
Filing
79309723
Registration
6669085
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
04/25/2023
Trademark type
Word
Nice classes
1, 5, 44
Filing date
12/21/2020
Registration date
03/15/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/15/2022
Last transaction
03/21/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Sapporo-shi, Hokkaido, JP
Examiner
FALK, JONATHAN ROBERT
Law office
M20
Current location
TMO LAW OFFICE 111
Holders and representatives
Holders
Goryo Chemical, Inc.
Representatives
Mary Margaret L. O'Donnell Blue Filament Law PLLC
Technical classification
Nice Classes
Class 1Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Reagents for research purposes; reagents for chemical analyses other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis; diagnostic reagents for scientific or research use; diagnostic reagents and preparationsexcept for medical or veterinary use; chemicalschemicals used in industrysulfonateschemicals for use in agricultureexcept fungicidesherbicidesinsecticides and parasiticides
Class 5
Pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of breastbraincolorectal and gastro-intestinal cancer; pharmaceutical preparations and substances used for detecting body fluids; pharmaceutical preparations and substances used for detecting pancreatic fluids; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of cancer; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of digestive system disorders; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of bone diseases; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of hyperlipidemia diseases; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of gastrointestinal diseases; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of hypoglycemia; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of sarcoma; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of immune system diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of hypertension; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of respiratory diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of skin disorders; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of multiple sclerosis; pharmaceutical preparations and substances for the diagnosis and treatmentthe prevention of cardiovascular diseases; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating central nervous system disorders; diagnostic biomarker reagents for medical purposes; veterinary diagnostic reagents; fluorescent diagnostic reagents for veterinary purposes; fluorescent diagnostic test reagents for veterinary purposes; diagnostic test reagents for medical purposes; fluorescent diagnostic test reagents for medical purposes; fluorescent diagnostic reagents for medical purposes; pharmaceutical preparations and other preparations for destroying verminfungicidesherbicides; fluorescent tracer agent for medical diagnostics or veterinary purposes; chemical reagents for veterinary purposes; fluorescent chemical reagents for veterinary purposes; chemical reagents for medical purposes; fluorescent chemical reagents for medical purposes; reagents for medical purposes; fluorescent reagents for medical purposes; medical diagnostic reagents and assays for testing of body fluids; medical diagnostic reagents and analysis samples for testing of body fluids; medical fluorescent diagnostic reagents and assays for testing of body fluids; medical fluorescent diagnostic reagents and analysis samples for testing of body fluids; medical clinical diagnostic reagents; fluorescent reagents for the clinical diagnosis; therapeutic drugs and agentsagents for the treatment of malignant tumors
Class 44
Medical testing services using fluorescent reagents for diagnostic or treatment purposes; medical analysis services for the analysisdiagnosistreatment of patients using fluorescent reagents provided by medical laboratories; medical analysis for the diagnosis and treatment of persons; medical diagnostic services; medical evaluation of breastbraincolorectal and gastro-intestinal cancer; medical diagnostic services using fluorescent reagents; medical evaluation services of breastbraincolorectal and gastro-intestinal cancer using fluorescent reagents; diagnosis of diseases; diagnosis of diseases using fluorescent reagents; diagnosis of cancer; diagnosis of cancer using fluorescent reagents; medical testing services relating to the diagnosis and treatment of disease; medical testing services relating to the diagnosis and treatment of disease using fluorescent reagents; medical analysis services relating to the diagnosis and treatment of disease using fluorescent reagents provided by medical laboratories; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis for the diagnosis of cancer; cancer screening services; cancer screening services using fluorescent reagents; medical services for the analysis of samples taken from patients provided by medical laboratories; fluorescence imaging examination for the medical diagnosis or treatment; providing information in the field of cancer preventionscreeningdiagnosis and treatment; providing medical information; providing medical information on diagnosis using fluorescent reagents; providing information on medical diagnosis using fluorescent reagents; medical analysis for the diagnosis of cancer using fluorescent reagents; rental of medical apparatus and installations; rental of medical diagnostic apparatus and installations; rental of medical diagnostic apparatus using fluorescent reagents and medical apparatus and installations using fluorescent reagents; rental of medical measuring apparatus
Publications
History of USPTO decisions and trademark events.
36 publications found
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/21/2023
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
03/21/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/20/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/05/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/11/2022
FIMP
FINAL DISPOSITION PROCESSED
08/11/2022
ES7R
TEAS SECTION 7 REQUEST RECEIVED
07/07/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/15/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
03/15/2022
GPNX
NOTIFICATION PROCESSED BY IB
01/10/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/28/2021
PUBO
PUBLISHED FOR OPPOSITION
12/28/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/22/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/22/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/22/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/19/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/19/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/19/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/16/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/16/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/16/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/16/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/16/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/16/2021
RFNT
REFUSAL PROCESSED BY IB
07/19/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/03/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/26/2021
RFRR
REFUSAL PROCESSED BY MPU
06/26/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/25/2021
CNRT
NON-FINAL ACTION WRITTEN
06/24/2021
DOCK
ASSIGNED TO EXAMINER
06/16/2021
MAFR
APPLICATION FILING RECEIPT MAILED
05/04/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/30/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/29/2021
Continuous trademark protection
Get notified about every new filing that threatens GORYO CHEMICAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.